Vimarsana
Biggest News Aggregation in the World

Page 30 - Two Decades News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Two Decades. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Two Decades Today - Breaking & Trending Today

Buenos Aires Times | Argentines recall nation's worst ever crisis, 20 years on - Vimarsana News

Buenos Aires Times | Argentines recall nation's worst ever crisis, 20 years on

This weekend marks two decades since Argentina's worst-ever financial crisis, which was accompanied by a period of civil and political unrest and rioting across the nation.

Australia's AUKUS nuclear submarines fleet may cost over USD 121 bn: Report - Vimarsana News

Australia's AUKUS nuclear submarines fleet may cost over USD 121 bn: Report

The new nuclear submarine fleet under the AUKUS partnership is expected to cost Australia as much as 171 billion Australian dollars (USD 121.7 billion) and will

Australia's AUKUS nuclear submarines fleet may cost over USD 121 bn: Report - Vimarsana News

Australia's AUKUS nuclear submarines fleet may cost over USD 121 bn: Report

The new nuclear submarine fleet under the AUKUS partnership is expected to cost Australia as much as 171 billion Australian dollars (USD 121.7 billion) and will

Australia's AUKUS nuclear submarines fleet may cost over USD 121 bn: Report - Vimarsana News

Australia's AUKUS nuclear submarines fleet may cost over USD 121 bn: Report

The new nuclear submarine fleet under the AUKUS partnership is expected to cost Australia as much as 171 billion Australian dollars (USD 121.7 billion) and will

Frontiers | Chagas Disease Drug Discovery in Latin America—A Mini Review of Antiparasitic Agents Explored Between 2010 and 2021 - Vimarsana News

Frontiers | Chagas Disease Drug Discovery in Latin America—A Mini Review of Antiparasitic Agents Explored Between 2010 and 2021

Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi that endangers almost 70 million people worldwide. The only two drugs that are currently approved for its treatment, benznidazole and nifurtimox, have controversial efficacy in adults and restricting safety issues, leaving thousands of patients without a suitable treatment. The neglect of Chagas disease is further illustrated by the lack of a robust and diverse drug discovery and development portfolio of new chemical entities, and it is of paramount importance to build a strong research and develo...